Article Text

Download PDFPDF

544 DELTA-1: A global, multicenter phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma
  1. Brian Gastman1,
  2. Omid Hamid2,
  3. Pippa Corrie3,
  4. Geoffrey Gibney4,
  5. Gregory Daniels5,
  6. Bartosz Chmielowski6,
  7. Sajeve Thomas7,
  8. Evidio Domingo-Musibay8,
  9. Donald Lawrence9,
  10. Yizhou Jiang10,
  11. Audrey Kennedy11,
  12. Jeff Aycock10,
  13. Ruben Alvarez-Rodriguez10,
  14. Paul Robbins10,
  15. John Le Gall10,
  16. Zachary Roberts10,
  17. Robert Hawkins10 and
  18. Amod Sarnaik12
  1. 1Cleveland Clinic, Cleveland, OH, USA
  2. 2The Angeles Clinic and Research Institute, Los Angeles, CA, USA
  3. 3Cambridge University Hospitals, Cambridge, UK
  4. 4Georgetown Lombardi Comprehensive Cancer, Washington, DC, USA
  5. 5University of California San Diego, La Jolla, CA, USA
  6. 6University of California Los Angeles, Los Angeles, CA, USA
  7. 7University of Florida, Orlando, FL, USA
  8. 8University of Minnesota Medical Center, Minneapolis, MN, USA
  9. 9Massachusetts General Hospital, Boston, MA, USA
  10. 10Instil Bio, Inc., Dallas, TX, USA
  11. 11Instil Bio, Inc, Dallas, TX, USA
  12. 12Moffitt Cancer Center, Tampa, FL, USA


Background Patients with advanced cutaneous melanoma and persistent disease after checkpoint inhibitor therapy have poor outcomes and limited treatment options, highlighting a significant unmet medical need.1 Autologous TIL cell therapies have shown promise in this population attributable, in part, to their intrinsic and patient-specific antitumor activity2; however, no such therapies are approved. Made from each patient‘s digested and cryopreserved tumor, ITIL-168 is an autologous TIL cell therapy manufactured to offer an unrestricted T-cell receptor repertoire. A single-center compassionate use clinical series demonstrated the feasibility and clinical utility of an earlier version of ITIL-168.3 DELTA-1 is a global, multicenter phase 2 study to evaluate efficacy and safety of ITIL-168. DELTA-1 will enroll patients with melanoma relapsed after or refractory to PD-1 inhibitors (PD-1i), patients intolerant to PD-1i, and patients whose best response to PD-1i was stable disease.

Methods Patients aged ≥18 years with histologically confirmed advanced cutaneous melanoma, ECOG performance status 0–1, and adequate organ function will be enrolled in 1 of 3 cohorts. Cohort 1 (n≈80) will include patients who relapsed after or were refractory to ≥1 prior line of systemic therapy, including a PD-1i and, if BRAF-mutated, a BRAFi ± MEKi. Cohorts 2 and 3 (n≈25 each) will include patients intolerant to PD-1i and those with stable disease after ≥4 doses of PD-1i, respectively. After tumor resection for TIL harvest, patients must have ≥1 remaining measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Patients with uveal, acral, or mucosal melanoma, prior allogeneic transplant or cell therapy, and with central nervous system (CNS) disorder or symptomatic and/or untreated CNS metastases are ineligible. Patients will receive 5 days of lymphodepleting chemotherapy (cyclophosphamide ×2 days overlapping with fludarabine ×5 days) followed by a single ITIL-168 infusion (≥5×109 cells) and supportive short course high-dose IL-2. The primary endpoint is objective response rate (ORR) per central review. Key secondary endpoints include duration of response, progression-free survival, overall survival, disease control rate, TIL persistence, and safety. Hypothesis testing of ORR will be performed for cohort 1. Two interim analyses will occur after 20 patients in cohort 1 have been followed for ≥28 days (safety) and evaluated for response ≥3 months after ITIL-168 infusion (futility). The primary analysis will occur when all patients in the cohort 1 modified intent-to-treat population have been followed for ≥6 months after the first posttreatment disease assessment.

Acknowledgements Medical writing support was provided by Christopher Waldapfel, PharmD, of Instil Bio, Inc, and Phylicia Aaron, PhD, of Nexus GG Science, with funding from Instil Bio, Inc.


  1. Schadendorf D, van Akkoi ACJ, Berking C, et al. Melanoma. Lancet 2018;392(10151):971–984.

  2. Borch TH, Anderson R, Ellebaek E, et al. Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma. J Immunother Cancer 2020;8(2):e000668.

  3. Hawkins RE, Jiang Y, Lorigan PC, et al. Clinical feasibility and treatment outcomes with unselected autologous tumor infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma. Cancer Res 2021;81(13):LB150.

Ethics Approval All patients will provide written informed consent. The study will be approved by the Institutional Review Board/Independent Ethics Committee at each site and conducted in accordance with the Good Clinical Practice Guidelines of the International Conference on Harmonisation.

Consent N/A; the abstract does not contain sensitive or identifiable patient information.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.